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Digestive (FFCD)/Fédération de Recherche en Chirurgie (FRENCH)Objective: To assess the impact of surgical technique in regard to morbidity
and mortality after neoadjuvant treatment for esophageal cancer.
Background: The SAKK trial 75/08 was a multicenter phase III trial
(NCT01107639) comparing induction chemotherapy followed by chemo-
radiation and surgery in patients with locally advanced esophageal cancer.
Methods: Patients in the control arm received induction chemotherapy with
cisplatin and docetaxel, followed by concomitant chemoradiation therapy
with cisplatin, docetaxel, and 45Gy. In the experimental arm, the same
regimen was used with addition of cetuximab. After completion of neo-adjuvant treatment, patients underwent esophagectomy. The experimental
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Copyright © 2020 Wolters Kluwer Health, Inc. Unarm received adjuvant cetuximab. Surgical outcomes and complications were
prospectively recorded and analyzed.
Results: Total of 259 patients underwent esophagectomy. Overall complication
rate was 56% and reoperation rate was 15% with no difference in complication
rates for transthoracic versus transhiatal resections (56% vs 54%, P¼ 0.77), nor
for video assisted thoracic surgeries (VATS) versus open transthoracic resec-
tions (67% vs 55%, P¼ 0.32). There was a trend to higher overall complication
rates in squamous cell carcinoma versus adenocarcinoma (65% vs 51%, P ¼
0.035), and a significant difference in ARDS in squamous cell carcinoma with
14% versus 2% in adenocarcinoma (P ¼ 0.0002). For patients with involved
lymph nodes, a lymph node ratio of0.1 was an independent predictor of PFS
(HR 2.5, P ¼ 0.01) and OS (HR 2.2, P ¼ 0.03).
Conclusions: This trial showed no difference in surgical complication rates
between transthoracic and transhiatal resections. For patients with involved
lymph nodes, lymph node ratio was an independent predictor of progression
free survival and overall survival.
Keywords: surgical outcomes after esophageal resection
(Ann Surg 2020;xx:xxx–xxx)
E sophageal cancer is the ninth most common cancer worldwide,with about 572,034 new cases (3.2% of all sites) estimated in
2018, but the sixth leading cause of cancer related mortality with
about 508,585 (5.3% of all sites) estimated deaths in 2018.1 Multi-
modality treatment much improved overall survival rates for patients
with resectable disease.2 However, esophageal cancer remains a
highly fatal disease with a 5-year overall survival rate of around
20%. Therefore, new treatment regiments are urgently needed. The
Swiss Group for Clinical Cancer Research (SAKK) trial 75/08 was a
multicenter phase III trial (NCT01107639) which investigated the
addition of the EGFR-antibody cetuximab to a regimen of induction
chemotherapy followed by chemoradiation and surgery for locally
advanced esophageal cancer. Design and primary results of this study
have been reported before.3 In brief, patients in the control arm
received 2 cycles of induction chemotherapy consisting of cisplatin
and docetaxel, followed by concomitant chemoradiation therapy
with cisplatin, docetaxel and 45Gy. In the experimental arm, the
same regimen was used with addition of cetuximab. After completion
of neoadjuvant treatment, patients proceeded to esophagectomy.
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von Holzen et al Annals of Surgery  Volume XX, Number XX, Month 2020Patients in the experimental arm received cetuximab after surgery as
adjuvant therapy in a 2-weekly manner for 6 cycles.
While there are a multitude of studies focusing on the surgical
aspects, many basic treatment principles remain controversial, such
as for example the optimal number of lymph nodes to be resected or
the appropriateness of oncologic aspects for minimally invasive
procedures and robotic procedures. Most controlled trials investigat-
ing surgical aspects of esophagectomy included low numbers of
patients, therefore this randomized phase-lll trial offered a great
opportunity to assess the impact of surgical technique in regard to
morbidity and mortality in the setting of an international, multicenter
trial after neoadjuvant multimodal treatment.
METHODS
Clinical Trial
The SAKK trial 75/08 was an intergroup, open-label phase III
trial performed according to declaration of Helsinki and GCP guide-
lines (NCT01107639). The protocol was approved by the ethics
committee of each participating institution, and all patients gave
written informed consent.
Design and primary results of this study have been reported
before.3 Briefly, previously untreated patients with resectable,
locally advanced, histologically confirmed squamous cell carcinoma
or adenocarcinoma of the thoracic esophagus, including the gastro-
esophageal junction (Siewert types I and II) were included.
Pretreatment staging consisted of complete medical history,
physical examination, upper endoscopy with biopsy, Positron Emission
Tomography - Computed Tomography (PET-CT) scan, computed
tomography scans of the chest and abdomen, endoscopic ultrasound
and bronchoscopy in case of tumors at or above the tracheal bifurcation.
In the control arm B, the preoperative treatment consisted of 2
cycles of induction chemotherapy followed by chemoradiation. Induc-
tion chemotherapy consisted of cisplatin 75 mg/m2 and docetaxel 75 mg/
m2 administered i.v. on days 1 and 22. Chemoradiation started after the
second induction chemotherapy cycle. Three-dimensional conformal
radiotherapy of 45 Gy (25 fractions of 1.8 Gy) was given over 5 weeks
with 6 to 18 MV photons. Concomitant chemotherapy consisted of i.v.
cisplatin 25 mg/m2 and docetaxel 20 mg/m2, administered weekly for
5 weeks on an outpatient basis. The desired interval for esophagectomy
in this study was within 4 to 7 weeks after administration of the last dose
of radiation. This time frame was chosen because of our experience from
earlier trials, and the very different rules about the timepoint of surgery
after neoadjuvant chemoradiation in different centers in Europe. Despite
the size of this trial including the international participation of 53 centers
in 4 European countries, only 9 cases had delayed surgery. Seven cases
were delayed due to logistical reasons, in the remaining 2 cases the
reason for delay remained unspecified.
In the experimental arm A the same neoadjuvant schedule
according to chemo- and radiotherapy was applied. In addition,
cetuximab 250 mg/m2 was weekly administered during the whole
chemotherapy (6 times) and chemoradiotherapy (5 times) with a
loading dose on d1 of 400 mg/m2. Within 3 to 6 weeks (as early as
possible) after surgery, cetuximab as adjuvant therapy was started in
a 2-weekly manner with 500 mg/m2.
Every case of death under therapy, or until 90 days postopera-
tively, triggered immediate subsequent evaluation by a medical
reviewer of SAKK together with the treating site to determine the
exact reason for death. Every death was classified as not-treatment-
related, direct or indirect complication of the treatment.
Surgical data and complications were assessed based on
predefined lists. Chart review and queries were performed to capture
missing data. Lymph node ratio was calculated as number of positive
lymph nodes divided by total number of harvested lymph nodes.
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Categorical data were summarized using frequency counts and
percentages and compared between subgroups using Fisher exact
test. Time-to-event endpoints were summarized by the median and
corresponding 95% confidence interval using the Kaplan-Meier
method. Effects of preselected covariates on these endpoints were
explored using Cox regression models.
Two-tailed tests with significance level 0.05 were used for all
analyses with no adjustment for multiple testing. All analyses were
conducted using SAS 9.4 (SAS Institute Inc) or R 3.4.3 (www.r-
project.org).
RESULTS
Population and Tumor Characteristics
A total of 300 patients with histologically confirmed esoph-
ageal squamous cell carcinoma or adenocarcinoma of the thoracic
esophagus or the gastroesophageal junction (Siewert I and II) were
randomized into the investigational arm or the control arm. Of these
patients, 259 successfully underwent surgical resection. Baseline
characteristics of these 259 patients undergoing surgical resection are
shown in Table 1. An abbreviated CONSORT diagram is shown in
Figure 1. The majority of the patients was male. Sex, age, and weight
was well balanced between the 2 groups. The median follow-up of
the patients in this trial was 4 years. All of the patients eligible for this
trial had a World Health Organization (WHO) performance status of
1, adequate hematologic, renal and hepatic function and normal
lung function, otherwise they could not be included.
Surgery
According to the protocol, esophageal en-bloc resection was
recommended by an abdomino-thoracal or a thoraco-abdomino-cervical
approach for squamous cell carcinoma with a complete two-field
lymphadenectomy. Routine reconstruction was done by a gastric tube.
For adenocarcinoma of the gastro-esophageal junction, Siewert type I, a
subtotal esophagectomy was the preferred operation. For adenocarcinoma
of the gastro-esophageal junction, Siewert type II, a transhiatal partial
esophagectomy, including total gastrectomy with adequate lymphadenec-
tomy and transhiatal esophagojejunostomy was recommended. The tran-
shiatal approach in this studywaschosen based on surgeon’s preferences at
that time in the participating centers in those 4 countries
In 87.3% (n ¼ 262) of the 300 patients analyzed, surgery was
performed. 12.7% (n¼ 38) patients did not undergo surgery because of
patient refusal in 3% (n¼ 9), progressive disease or extent of disease in
3% (n¼ 9), comorbidities in 2% (n¼ 6), performance status in 1.7% (n
¼ 5), death during or after neoadjuvant treatment in 1.3% (n¼ 4), trial
stop due to unacceptable toxicity during neoadjuvant treatment in 1%
(n ¼ 3) and ineligibility in 0.7% (n ¼ 2). Of the patients that did
undergo surgery, 3 did not undergo resection due to the extent of
disease intraoperatively. Of the 259 resected patients, R0 Resection
was achieved in 96.1% (n ¼ 249) with no difference between the
treatment groups. The rate of margin positivity in Siewert I and II
tumors was 1.2% (n ¼ 1) and 5.8% (n ¼ 3), respectively.
Overall, the transthoracic approach was chosen in 75.3% (n¼
195), and the transhiatal approach in 23.6% (n ¼ 61). The approach
chosen differed based on the histology of the tumor. For adenocarci-
noma, 69.0% (n¼ 118) of procedures were performed transthoracic,
and 29.2% (n ¼ 50) transhiatal, versus for squamous cell carcinoma,
87.5% (n ¼ 77) of the procedures were performed transthoracic, and
only 12.5% (n ¼ 11) transhiatal.
Of all the procedures that were performed with a transthoracic
approach, 15.4% (n ¼ 30) were performed as VATS.
According to the approach chosen, the level of anastomosis
was placed thoracal in 67.6% (n ¼ 175) and cervical in 31.7%
 2020 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 1. Baseline Patient Characteristics of Patients Undergoing Surgical Resection
Investigational Arm (N ¼ 131) Control Arm (N ¼ 128)
Age (yrs, median (range)) 61 (41–75) 61 (36–75)
Sex
Male 115 (88%) 113 (88%)
Female 16 (12%) 15 (12%)
Histologic type
Adenocarcinoma 86 (66%) 85 (66%)
Squamous cell carcinoma 45 (34%) 43 (34%)
Localization (main tumor load)
Upper part (5 cm from thoracic inlet to tracheal bifurcation) 5 (4%) 3 (2%)
Lower part (tracheal bifurcation to esophagogastric junction) 57 (44%) 62 (48%)
Esophagogastric junction 69 (53%) 63 (49%)
Siewert type
Type I 39 (30%) 40 (31%)
Type II 30 (23%) 23 (18%)
Clinical T stage
uT2 20 (15%) 20 (16%)
uT3 108 (82%) 103 (80%)
uT4a 3 (2%) 5 (4%)
Clinical N stage
N0 15 (11%) 12 (9%)
Nþ 116 (89%) 116 (91%)
WHO performance Status
0 86 (66%) 75 (59%)
1 43 (33%) 53 (41%)
WHO indicates World Health Organization.
Annals of Surgery  Volume XX, Number XX, Month 2020 Surgical Outcomes for EAC Resection(n ¼ 82). Again, this slightly differed based on the histology. For
adenocarcinoma 28.1% (n¼ 48) were cervical, and 70.8% (n¼ 121)
thoracal, whereas for squamous cell carcinoma 38.6% (n¼ 34) were
cervical and 61.4% (n ¼ 54) thoracal.
Surgical data according to histology is summarized in Table 2.
There was no difference observed with the addition of cetuximab.
Postoperative Complications
The overall complication rate in this trial was 55.6% (n ¼
144), with a reoperation rate of 15.4% (n ¼ 40) (calculated as
percentage of patients having postoperative complications or reop-
erations, resp.). Stents were rarely placed (only 0.8% n ¼ 2). There
FIGURE 1. Abbreviated CON-
SORT diagram.
 2020 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2020 Wolters Kluwer Health, Inc. Unwas no difference in overall complication rates between the investi-
gational arm (52.7% n¼ 69) and the control arm (58.6% n¼ 75), nor
was there any difference in the reoperation rate (16% (n¼ 21) versus
14.8% (n ¼ 18), respectively).
The major complications in this trial were infections in 36.7%
(n ¼ 95), with pneumonia most common with 23.2% (n ¼ 60),
anastomotic leak in 17% (n ¼ 44) and Acute respiratory distress
syndrome (ARDS) in 5.8% (n¼ 15) of the patients. There was a trend
to higher overall complication rates and reoperation rates in squa-
mous cell carcinoma versus adenocarcinoma (64.8% (n¼ 57) versus
50.9% (n ¼ 87), P ¼ 0.035, and 18.2% (n ¼ 16) versus 14.0% (n ¼
24), P ¼ 0.468, respectively). However this did not reach statistical
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n (%) n (%)
Resection
R0 165 (96.5%) 84 (95.5%)
R1 5 (2.9%) 4 (4.5%)
Localization of residual tumor
Distal/gastric margin 1 (0.6%)
Proximal margin 2 (1.2%)
Radial margin 3 (1.8%) 4 (4.5%)
Approach
Transthoracic 118 (69.0%) 77 (87.5%)
Transhiatal 50 (29.2%) 11 (12.5%)
For transthoracic approach
Open 100 (58.5%) 66 (75.0%)
Thoracoscopically (VATS) 19 (11.1%) 11 (12.5%)
Level of anastomosis
Cervical 48 (28.1%) 34 (38.6%)
Thoracic 121 (70.8%) 54 (61.4%)
TABLE 3. Major Postoperative Complication Rates Based on Histo
Adenocarcinoma (N ¼ 171) Squ
n (%)
Infection 61 (35.7%)
Type of infection (more than 1 possible)
Abscess 4 (2.3%)
C. diff colitis 2 (1.2%)
Empyema 9 (5.3%)





Port infection 1 (0.6%)
SIRS/Sepsis 7 (4.1%)
Urinary tract infection 4 (2.3%)
Wound infection 4 (2.3%)
ARDS 3 (1.8%)
Anastomotic leak 24 (14.0%)
Other complications 56 (32.7%)
Transthoracal (N ¼ 195)
n (%)
Infection 67 (34.4%)
Specify infection (more than 1 applicable)
Abscess 2 (1.0%)
C. diff colitis 1 (0.5%)
Empyema 5 (2.6%)








Wound infection 4 (2.1%)
ARDS 13 (6.7%)
Anastomotic leak 33 (16.9%)
Other complications 76 (39.0%)
Other complications include: aortesophageal fistula, bleeding, bronchesophageal fistula, c
pulmonary embolism, recurrens paresis, renal insufficiency, small bowel injury, splenic infa
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ARDS in squamous cell carcinoma with 13.6% (n ¼ 12) versus
only 1.8% (n ¼ 3) in adenocarcinoma (P ¼ 0.0002). Furthermore,
pneumonia was also more frequent in squamous cell carcinoma than
in adenocarcinoma [31.8% (n ¼ 28) and 18.7% (n ¼ 32), resp.].
Anastomotic leak rate was higher in squamous cell carcinomas as
well [22.7% (n¼ 20) vs 14.0% (n¼ 24)]. ARDS was correlated with
anastomotic leak and this correlation was statistically highly signifi-
cant. ARDS occurred in 15.9% (n ¼ 7) of patients with anastomotic
leak versus 3.7% (n ¼ 8) in patients without leak (P ¼ 0.006). The
same held true for postoperative pneumonia. There was an increased
rate of pneumonia for patients having an anastomotic leak with
40.9% (n ¼ 18) versus 19.5% (n ¼ 42), P ¼ 0.005. As expected, the
overall complication rate was higher with resection of other organs
[61.8% (n ¼ 47) vs 53.0% (n ¼ 97), P ¼ 0.22].
There was no difference in complication rates for transthoracic
versus transhiatal operations [56.4% (n ¼ 110) vs 54.1% (n ¼ 33), P
¼ 0.77], nor was there a difference in reoperation rates for transtho-
racic versus transhiatal operations [16.9% (n¼ 33) vs 11.5% (n¼ 7),
P ¼ 0.42]. For the transthoracic approach, complication rates were
logy and Surgical Approach
amous Cell Carcinoma (N ¼ 88) Total (N ¼ 259)
n (%) n (%)
34 (38.6%) 95 (36.7%)
1 (1.1%) 5 (1.9%)
1 (1.1%) 3 (1.2%)
9 (3.5%)
2 (0.8%)
1 (1.1%) 5 (1.9%)
1 (0.4%)
1 (0.4%)
28 (31.8%) 60 (23.2%)
1 (0.4%)
5 (5.7%) 12 (4.6%)
2 (2.3%) 6 (2.3%)
2 (2.3%) 6 (2.3%)
12 (13.6%) 15 (5.8%)
20 (22.7%) 44 (17.0%)
42 (47.7%) 98 (37.8%)















ardiac arrest / atrial fibrillation, chylothorax, DVT, hepatic insufficiency, pneumothorax,
rction, TIA/neuro, tracheal injury.
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TABLE 4. Treatment Related Mortality Based on Histology and Surgical Approach
Adenocarcinoma Squamous Cell Carcinoma
N Death n (%) N Death n (%)
Postoperative total 171 10 (5.8%) 88 5 (5.7%)
- In-hospital 171 6 (3.5%) 88 3 (3.4%)
- 30 d 171 7 (4.1%) 88 4 (4.5%)
- 90 d 171 7 (4.1%) 88 5 (5.7%)
Transthoracal Transhiatal
N Death n (%) N Death n (%)
Postoperative total 195 12 (6.2%) 61 3 (4.9%)
- In-hospital 195 7 (3.6%) 61 2 (3.3%)
- 30d 195 9 (4.6%) 61 2 (3.3%)
- 90d 195 11 (5.6%) 61 1 (1.6%)
Annals of Surgery  Volume XX, Number XX, Month 2020 Surgical Outcomes for EAC Resectionsimilar for VATS versus open procedures [66.7% (n ¼ 20) vs 54.8%
(n ¼ 91), P ¼ 0.32].
There was a trend to a higher overall complication rate for
cervical versus thoracic anastomosis (63.4% (n ¼ 52) vs 52.6% (n ¼
92), P ¼ 0.11). This difference was mainly due to the anastomotic
leak rate. There was a significantly higher rate of anastomotic
leakages for cervical versus thoracic anastomosis [25.6% (n ¼ 21)
vs 13.1% (n ¼ 23), P ¼ 0.02). According to the Esophageal
Complications Consensus Group (ECCG) score of complications
after esophagectomy, 45.5% (n¼ 20) of patients with an anastomotic
leak underwent a reoperation, and could therefore be classified
retrospectively as Type III anastomotic leak. The remaining 24
patients (54.5%) were classified as a Type I/II leak according to
the ECCG classification, as these types could not be separated based
on the data collected. Major complications are summarized in Table 3
according to histology and surgical approach. The specific reasons
for take back to the operating room depending on the presence of an
anastomotic leak are shown in Table 5. As mentioned above, there
was no statistical difference with the addition of cetuximab.
Mortality
In total, 15 out of the 259 patients who underwent surgical
resection died in the postoperative period due to complications for an
overall mortality rate of 6% with no significant difference between
the investigational arm and the control arm. Table 4 shows the
detailed postoperative in hospital, 30-day and 90-day mortality rates
of this trial according to histology and surgical approach.
TABLE 5. Reoperations Based on Presence of Anastomotic
Leak
No Anastomotic
Leak (N ¼ 215)
Anastomotic
leak (N ¼ 44)
n (%) n (%)
No Reoperation 195 (90.7%) 24 (54.5%)
Reoperation 20 (9.3%) 20 (45.5%)
Type of reoperation
Drainage 2 (0.9%) 1 (2.3%)
Endovac 1 (2.3%)
Laryngoplasty 1 (0.5%)
Other nonrelated procedure 2 (4.5%)
Revision 16 (7.4%) 13 (29.5%)
Stent 2 (4.5%)
Wound revision 1 (0.5%) 1 (2.3%)
 2020 Wolters Kluwer Health, Inc. All rights reserved.
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The median length of stay was 21 days (range 10–211) for the
transthoracic approach and 18 days (range 3–144) for the transhiatal
approach (P ¼ 0.17). For patients with a transthoracic approach, the
median length of stay was 24.5 days (range 13–211) for VATS
procedures, and 20 days (range 10–170) for open procedures (P¼ 0.1).
Lymph Node Resected, Lymph Node Ratio and
Prognosis
Median number of lymph nodes resected was 19.0 for the
transthoracic and 18.0 for the transhiatal approach. In total 32% (n¼
83) of the patients had involved lymph nodes, with 29.0% (n¼ 38) of
the patients in the investigational arm, and 35.2% (n¼ 45) of patients
in the control arm.
The total number of involved lymph nodes was a predictor of
progression free survival (PFS) [hayard ratio (HR) 1.06 95% CI (1.02–
1.10), P¼ 0.004], overall survival (OS) (HR 1.07 95% CI [1.02–1.11],
P ¼ 0.003), time to locoregional failure [HR ¼ 1.08 95% CI (1.03–
1.14), P¼ 0.003] and time to distant failure [HR¼ 1.07 95% CI (1.01–
1.12), P ¼ 0.01] in univariable Cox regression models.
For patients with involved lymph nodes, lymph node ratio of
0.1 versus <0.1 was an independent predictor of PFS [HR 2.5 95%
CI (1.2–5.1), P¼ 0.01], OS [HR 2.2 95% CI (1.1–4.4), P¼ 0.03], time
to locoregional failure [HR 4.1 95% CI (1.3–13.7), P¼ 0.02] and time
to distant failure [HR 2.9 95% CI (1.1–7.4), P ¼ 0.03] [Fig. 2 A–D].
Survival
Overall survival data of this trial has been reported before.3
The median progression free survival was 35 months in the investi-
gational arm versus 24 months in the control arm (HR ¼ 0.79, P ¼
0.13). The median overall survival was 61 months in the investiga-
tional arm versus 36 months in the control arm (HR ¼ 0.73, P ¼
0.055), with 4-year survival rates of 56% versus 43%, respectively.
DISCUSSION
In this study, we found that addition of cetuximab to neo-
adjuvant therapy for esophageal cancer is safe as demonstrated by an
overall low postoperative mortality rate. The SAKK trial 75/08 was a
large European multicenter phase III trial conducted in Switzerland,
Germany, Austria and France, and most patients were operated in low
to median case load hospitals. The patient cohort in this trial was
comparable to other published series,2 with most patients having
advanced disease stages as expected by the trial design. The total
postoperative mortality rate of 6% was consistent with other con-
temporary published series for multicenter trials of multimodality
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FIGURE 2. A. Kaplan-Meier-Plot for PFS by lymph node ratio (cut-off 0.1) for patients with involved lymph nodes. B. Kaplan-Meier-
Plot for OS by lymph node ratio (cut-off 0.1) for patients with involved lymph nodes. C. Kaplan-Meier-Plot for time to locoregional
failure after R0 resection by lymph node ratio (cut-off 0.1) for patients with involved lymph nodes. D. Kaplan-Meier-Plot for time to
distant failure after R0 resection by lymph node ratio (cut-off 0.1) for patients with involved lymph nodes.
von Holzen et al Annals of Surgery  Volume XX, Number XX, Month 2020treatment for esophageal cancer.4–6 Regarding overall and procedure
specific complications, the observed rates were again consistent with
those published in the literature. For example, a pulmonary compli-
cation rate of 45.2%, an anastomotic leak rate of 26.0% and a cardiac
complication rate of 18.9% were described in the CROSS trial.2 The
overall complication rate of 55.6% in this study corresponds to the
overall incidence of complications of 59.0% found in a recent
publication of the ECCG involving 24 high-volume esophageal
surgical centers in 14 countries.7 Again, the good results in this
study were achieved despite most of the patients being operated on in
low to median case load hospital. Furthermore, in our trial, no
difference was found regarding overall complication rates and out-
comes between transthoracic and transhiatal esophageal resections,
nor between adenocarcinomas and squamous cell carcinomas. How-
ever, there was a significant difference in the frequency of ARDS,
with 13.6% in squamous cell carcinoma versus only 1.8% in adeno-
carcinoma (P ¼ 0.0002). Furthermore, pneumonia was also more
frequent in squamous cell carcinoma than in adenocarcinoma (31.8%
and 18.7%, resp.). Possible explanations for this difference might be
the generally higher location of the squamous cell carcinomas,
placing more lung tissue into the neoadjuvant radiation field, and
the location of the anastomosis, as ARDS was correlated with
anastomotic leak. The same held true for postoperative pneumonia,
where there was an increased rate of pneumonia for patients having
6 | www.annalsofsurgery.com
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for transthoracic versus transhiatal operations. Importantly, there was
no difference in complication rates for minimally invasive versus
open procedures. This was consistent with the emerging literature
about the role of minimally invasive surgery in esophageal cancer.8,9
Regarding the site of the anastomosis, there was a trend to a higher
overall complication rate for cervical versus thoracic anastomosis,
but this failed to reach statistical significance. Most of the patients
who have complications after esophagectomy have more than one
complication. Unfortunately, at the conception of this study, the
grading of the severity of surgical complications according to the
Clavien Dindo classification was not included. Although a complete
classification or even the comprehensive complication Index would
be beneficial, we unfortunately do not have this data.
The median length of stay of 21 days was fairly long in this
study compared to other published series.10 However, this might in
part be explained by the traditions of the Health care systems in
Switzerland, Germany, Austria and France where length of stay
seems to be longer.
The number of lymph nodes that should be resected during
esophagectomy remains controversial. Especially the effects of neo-
adjuvant chemoradiation therapy on lymph node retrieval during
esophagectomy remain unclear. A recent study by Giugliano et al,
comparing the quantitative lymph node assessment in patients after R0
 2020 Wolters Kluwer Health, Inc. All rights reserved.
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that total lymph node counts were significantly lower in the chemo-
radiation therapy group, whereas positive lymph node counts and
lymph node ratios did not differ from the upfront surgery group. The
overall survival was decreased within the induction therapy cohort
among those who had any positive lymph nodes retrieved at surgery.11
These results were consistent with the findings in our study. It is well
known in the literature that the N status, or positive lymph nodes are an
independent prognostic factor. In our study, the total number of
involved lymph nodes was a predictor of progression free survival
and overall survival in univariable Cox regression models. It has been
shown previously that the number of involved lymph nodes can be used
to predict the likelihood of systemic disease in patients with esophageal
cancer, and thus survival of these patients.12 In our study, for patients
with involved lymph nodes, a lymph node ratio of 0.1 versus <0.1,
and a lymph node ratio of 0.2 versus <0.2, was an independent
predictor of progression free survival and overall survival. Lymph node
ratio has been found to have prognostic significance in several tumors.
There are only a few reports in the literature that recognized the
prognostic significance of the lymph node ratio in esophageal can-
cer,13,14 confirming our findings.
In conclusion, in a large European multicenter phase III trial,
we found that addition of cetuximab to neoadjuvant therapy for
esophageal cancer was safe as demonstrated by an overall low
postoperative mortality rate and complication rate. There was no
difference in postoperative complication rates regarding the surgical
approach chosen. For patients with involved lymph nodes, lymph
node ratio was an independent predictor of progression free survival
and overall survival.
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